MXPA00010070A - Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis. - Google Patents
Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.Info
- Publication number
- MXPA00010070A MXPA00010070A MXPA00010070A MXPA00010070A MXPA00010070A MX PA00010070 A MXPA00010070 A MX PA00010070A MX PA00010070 A MXPA00010070 A MX PA00010070A MX PA00010070 A MXPA00010070 A MX PA00010070A MX PA00010070 A MXPA00010070 A MX PA00010070A
- Authority
- MX
- Mexico
- Prior art keywords
- angiogenesis inhibitor
- antibody
- enhancement
- administration
- fusion protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Abstract
Se describen composiciones y metodos para mejorar una respuesta inmune citocidal dirigida contra un tipo celular preseleccionado en un mamifero. Los metodos y composiciones dependen de una combinacion de un inmunoconjugado anticuerpo- citoquina y un inhibidor de angiogenesis. Una vez administrado al mamifero, el inmunoconjugado induce una respuesta inmune contra el tipo celular preseleccionado, por ejemplo, una celula cancerosa la cual, como resultado de la sinergia con el inhibidor de angiogenesis, es mayor que la respuesta inmune inducida por el inmunoconjugado solo. Los metodos y composiciones son particularmente utiles al eliminar tumores solidos o celulas viralmente infectadas en un mamifero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8186398P | 1998-04-15 | 1998-04-15 | |
PCT/US1999/008335 WO1999052562A2 (en) | 1998-04-15 | 1999-04-15 | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00010070A true MXPA00010070A (es) | 2004-03-10 |
Family
ID=22166892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00010070A MXPA00010070A (es) | 1998-04-15 | 1999-04-15 | Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20040180035A1 (es) |
EP (1) | EP1071468B1 (es) |
JP (1) | JP2002511432A (es) |
CN (1) | CN1318092C (es) |
AT (1) | ATE329622T1 (es) |
AU (1) | AU758860B2 (es) |
BR (1) | BR9909583A (es) |
CA (1) | CA2328076C (es) |
CZ (1) | CZ20003767A3 (es) |
DE (1) | DE69931908T2 (es) |
ES (1) | ES2267263T3 (es) |
HK (1) | HK1038882A1 (es) |
HU (1) | HUP0101352A3 (es) |
MX (1) | MXPA00010070A (es) |
NO (1) | NO20005155L (es) |
PL (1) | PL343462A1 (es) |
RU (1) | RU2229305C2 (es) |
WO (1) | WO1999052562A2 (es) |
ZA (1) | ZA200005475B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1037927T3 (da) * | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
BR9913331A (pt) * | 1998-08-25 | 2001-05-15 | Lexigen Pharm Corp | Expressão e exportação de inibidores de angiogênese como imunofusinas |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
AU3497901A (en) | 2000-02-10 | 2001-08-20 | Massachusetts Eye & Ear Infirm | Methods and compositions for treating conditions of the eye |
DE60122286T2 (de) | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
BR0112111A (pt) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
CA2440221C (en) | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
WO2003048334A2 (en) | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
WO2005063820A2 (en) * | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
EP1699821B1 (en) * | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
WO2005066348A2 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
KR20070085886A (ko) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | 감소된 면역원성의 il-7 변이체 |
DE602006021335D1 (de) * | 2005-10-21 | 2011-05-26 | Hoffmann La Roche | Methode zur rekombinanten expression eines polyeptids |
JP5175214B2 (ja) * | 2005-12-30 | 2013-04-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 改良された安定性を有するインターロイキン−12p40変種 |
BRPI0620795A2 (pt) | 2005-12-30 | 2011-11-22 | Merck Patent Ges Mit Beschronkter Haftung | anticorpos anti-cd19 imunogenicidade reduzida |
GB2441789B (en) * | 2006-09-18 | 2012-03-28 | Angus Buchan Gordon | Use of a Tumour Volume Measuring Device |
CN102405230A (zh) | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | 具有修饰的FcRn结合位点的抗体融合蛋白 |
EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN104830901A (zh) * | 2015-01-21 | 2015-08-12 | 武汉友芝友生物制药有限公司 | 一种鼠肿瘤模型的构建方法及其应用 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
AU2018297248A1 (en) | 2017-07-03 | 2020-02-20 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4469797A (en) * | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5643565A (en) * | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5120525A (en) * | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
ATE123065T1 (de) * | 1989-07-07 | 1995-06-15 | Takeda Chemical Industries Ltd | Proteine und deren herstellung. |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
EP0541716A1 (en) * | 1990-07-27 | 1993-05-19 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
ATE218889T1 (de) * | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
EP0615451B1 (en) * | 1992-05-26 | 2005-12-07 | Immunex Corporation | Novel cytokine that binds cd30 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
CA2147499C (en) * | 1992-11-05 | 2010-10-19 | Ron S. Israeli | Prostate-specific membrane antigen |
US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
HUT73876A (en) * | 1993-04-29 | 1996-10-28 | Abbott Lab | Erythropoietin analog compositions and methods |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
JP3880064B2 (ja) * | 1994-04-26 | 2007-02-14 | ザ チルドレンズ メディカル センター コーポレイション | アンジオスタチンおよび血管形成の抑制におけるその使用 |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
DE69523857T2 (de) * | 1994-09-16 | 2002-06-13 | Merck Patent Gmbh | Immunokonjugate |
US6485726B1 (en) * | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5552524A (en) * | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US6169070B1 (en) * | 1995-03-10 | 2001-01-02 | Genentech, Inc. | Mer receptor activation by gas6 |
US5719266A (en) * | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
KR19990028388A (ko) * | 1995-06-30 | 1999-04-15 | 피터 지. 스트링거 | 당뇨병 치료 방법 |
US6406689B1 (en) * | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
ATE248912T1 (de) * | 1995-10-23 | 2003-09-15 | Childrens Medical Center | Therapeutische antiangiogenische zusammensetzungen und verfahren |
US6620413B1 (en) * | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CA2205757C (en) * | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
EP0927033A1 (en) * | 1996-07-02 | 1999-07-07 | Bar-Ilan University | Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
ATE218143T1 (de) * | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
PT973550E (pt) * | 1997-04-11 | 2003-01-31 | Searle & Co | Anticorpos antagonistas anti-integrina avb3 |
DK1037927T3 (da) * | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
CA2328081A1 (en) * | 1998-04-17 | 1999-10-28 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
AU3655899A (en) * | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
BR9913331A (pt) * | 1998-08-25 | 2001-05-15 | Lexigen Pharm Corp | Expressão e exportação de inibidores de angiogênese como imunofusinas |
US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
AU778939B2 (en) * | 1999-01-07 | 2004-12-23 | Emd Lexigen Research Center Corp. | Expression and export of anti-obesity proteins as Fc fusion proteins |
US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
EP1187852B1 (en) * | 1999-05-19 | 2007-08-08 | EMD Lexigen Research Center Corp. | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
WO2001088117A2 (en) * | 2000-05-12 | 2001-11-22 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
BR0112111A (pt) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina |
US20040043457A1 (en) * | 2001-01-18 | 2004-03-04 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
ATE400030T1 (de) * | 2001-02-19 | 2008-07-15 | Merck Patent Gmbh | Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität |
MXPA03007323A (es) * | 2001-02-19 | 2003-12-12 | Merck Patent Gmbh | Proteinas artificiales con inmunogenicidad reducida. |
CA2440221C (en) * | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
WO2003048334A2 (en) * | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
-
1999
- 1999-04-15 EP EP99917558A patent/EP1071468B1/en not_active Expired - Lifetime
- 1999-04-15 WO PCT/US1999/008335 patent/WO1999052562A2/en active IP Right Grant
- 1999-04-15 ES ES99917558T patent/ES2267263T3/es not_active Expired - Lifetime
- 1999-04-15 PL PL99343462A patent/PL343462A1/xx unknown
- 1999-04-15 CN CNB998072494A patent/CN1318092C/zh not_active Expired - Fee Related
- 1999-04-15 AT AT99917558T patent/ATE329622T1/de not_active IP Right Cessation
- 1999-04-15 JP JP2000543172A patent/JP2002511432A/ja not_active Withdrawn
- 1999-04-15 MX MXPA00010070A patent/MXPA00010070A/es active IP Right Grant
- 1999-04-15 CZ CZ20003767A patent/CZ20003767A3/cs unknown
- 1999-04-15 AU AU35650/99A patent/AU758860B2/en not_active Ceased
- 1999-04-15 DE DE69931908T patent/DE69931908T2/de not_active Expired - Lifetime
- 1999-04-15 RU RU2000125521/15A patent/RU2229305C2/ru not_active IP Right Cessation
- 1999-04-15 CA CA002328076A patent/CA2328076C/en not_active Expired - Fee Related
- 1999-04-15 HU HU0101352A patent/HUP0101352A3/hu unknown
- 1999-04-15 BR BR9909583-1A patent/BR9909583A/pt not_active Application Discontinuation
-
2000
- 2000-10-06 ZA ZA200005475A patent/ZA200005475B/xx unknown
- 2000-10-13 NO NO20005155A patent/NO20005155L/no not_active Application Discontinuation
-
2002
- 2002-01-21 HK HK02100466.3A patent/HK1038882A1/zh unknown
-
2003
- 2003-11-14 US US10/714,165 patent/US20040180035A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU758860B2 (en) | 2003-04-03 |
CA2328076A1 (en) | 1999-10-21 |
DE69931908D1 (de) | 2006-07-27 |
CN1305386A (zh) | 2001-07-25 |
WO1999052562A2 (en) | 1999-10-21 |
EP1071468A2 (en) | 2001-01-31 |
NO20005155D0 (no) | 2000-10-13 |
BR9909583A (pt) | 2002-01-15 |
DE69931908T2 (de) | 2007-01-11 |
NO20005155L (no) | 2000-12-13 |
PL343462A1 (en) | 2001-08-13 |
US20040180035A1 (en) | 2004-09-16 |
CA2328076C (en) | 2009-10-06 |
HK1038882A1 (zh) | 2002-04-04 |
AU3565099A (en) | 1999-11-01 |
ES2267263T3 (es) | 2007-03-01 |
ZA200005475B (en) | 2001-11-13 |
JP2002511432A (ja) | 2002-04-16 |
HUP0101352A3 (en) | 2003-08-28 |
WO1999052562A3 (en) | 1999-11-18 |
EP1071468B1 (en) | 2006-06-14 |
CZ20003767A3 (cs) | 2002-01-16 |
ATE329622T1 (de) | 2006-07-15 |
HUP0101352A2 (hu) | 2001-08-28 |
CN1318092C (zh) | 2007-05-30 |
RU2229305C2 (ru) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL343462A1 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor | |
WO1999053958A3 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor | |
NO20026245D0 (no) | Forbedring av antistoff-cytokin-fusjonsprotein-formidlede immunresponser ved kombinert behandling med immunocytokin-opptaksökende midler | |
NO20004911D0 (no) | Antitumormiddel | |
EA200200808A1 (ru) | Модифицированные цитокины, предназначенные для применения в терапии рака | |
EP1178796A4 (en) | AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE | |
ES2188261T3 (es) | Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides. | |
AU2002350623A1 (en) | Targeted thrombosis by tissue factor polypeptides | |
ES2181461T3 (es) | Utilizacion de nuevos agentes inductores de muerte celular en sinergia con interferones. | |
IL114382A0 (en) | Cancer therapy using lymphotoxin | |
AP2000001984A0 (en) | Combination of protein farnesyltrandferase and HMG COA reductase inhibitors and their use to treat cancer. | |
WO2003028001A8 (en) | Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol | |
EA200100098A1 (ru) | Соли пароксетина | |
AU2821000A (en) | Matrix protein compositions for induction of apoptosis | |
ATE417926T1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
EP1234585A3 (en) | Methods and compositions for the prevention or treatment of cancer | |
FI961339A0 (fi) | Triaryylieteenijohdannaiset käytettäväksi hoidossa | |
DK1227826T3 (da) | Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf | |
ES1044990U (es) | Union perfeccionada para estructuras de muebles, particularmente mesas. | |
EA200500210A1 (ru) | Конъюгаты стероидов, их получение и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights | ||
HC | Change of company name or juridical status |